Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
4.430
-0.060 (-1.34%)
At close: Feb 21, 2025, 4:00 PM
4.420
-0.010 (-0.23%)
After-hours: Feb 21, 2025, 4:00 PM EST
Vanda Pharmaceuticals Employees
Vanda Pharmaceuticals had 203 employees as of December 31, 2023. The number of employees decreased by 87 or -30.00% compared to the previous year.
Employees
203
Change (1Y)
-87
Growth (1Y)
-30.00%
Revenue / Employee
$979,172
Profits / Employee
-$93,103
Market Cap
258.34M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
VNDA News
- 8 days ago - Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 16 days ago - Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 - PRNewsWire
- 26 days ago - Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis - PRNewsWire
- 6 weeks ago - Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review - PRNewsWire
- 2 months ago - Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity - Seeking Alpha
- 2 months ago - Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera - PRNewsWire
- 2 months ago - Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc. - Business Wire